APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pituitary ACTH Hypersecretion Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pituitary ACTH Hypersecretion Drug Industry Research Report 2026

26 December 2025120 pages

Choose your research edition.

Industry ResearchPituitary ACTH Hypersecretion Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pituitary ACTH Hypersecretion Drug Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Pituitary ACTH Hypersecretion Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pituitary ACTH Hypersecretion Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pituitary ACTH Hypersecretion Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pituitary ACTH Hypersecretion Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pituitary ACTH Hypersecretion Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Pituitary ACTH Hypersecretion Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pituitary ACTH Hypersecretion Drug include Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, Cyclacel Pharmaceuticals, Inc., ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Orphagen Pharmaceuticals, Inc. and Pfizer Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pituitary ACTH Hypersecretion Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pituitary ACTH Hypersecretion Drug Market by Company

Alder Biopharmaceuticals Inc.

Corcept Therapeutics Incorporated

Cortendo AB

Cyclacel Pharmaceuticals, Inc.

ElexoPharm GmbH

Ipsen S.A.

Isis Pharmaceuticals, Inc.

Orphagen Pharmaceuticals, Inc.

Pfizer Inc.

Novartis AG

Pituitary ACTH Hypersecretion Drug Segment by Type

ISIS-GCCRRx

CORT-125134

COR-005

BIM-23A758

ATR-101

AT-814

Others

Pituitary ACTH Hypersecretion Drug Segment by Application

Clinic

Hospital

Others

Pituitary ACTH Hypersecretion Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pituitary ACTH Hypersecretion Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pituitary ACTH Hypersecretion Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pituitary ACTH Hypersecretion Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Pituitary ACTH Hypersecretion Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Pituitary ACTH Hypersecretion Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Pituitary ACTH Hypersecretion Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pituitary ACTH Hypersecretion Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Pituitary ACTH Hypersecretion Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Pituitary ACTH Hypersecretion Drug Revenue of Manufacturers (2021-2026) Table 9. Global Pituitary ACTH Hypersecretion Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Pituitary ACTH Hypersecretion Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Pituitary ACTH Hypersecretion Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Product Type & Application Table 14. Global Pituitary ACTH Hypersecretion Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Pituitary ACTH Hypersecretion Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Alder Biopharmaceuticals Inc. Company Information Table 19. Alder Biopharmaceuticals Inc. Business Overview Table 20. Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 22. Alder Biopharmaceuticals Inc. Recent Developments Table 23. Corcept Therapeutics Incorporated Company Information Table 24. Corcept Therapeutics Incorporated Business Overview Table 25. Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Product Portfolio Table 27. Corcept Therapeutics Incorporated Recent Developments Table 28. Cortendo AB Company Information Table 29. Cortendo AB Business Overview Table 30. Cortendo AB Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Cortendo AB Pituitary ACTH Hypersecretion Drug Product Portfolio Table 32. Cortendo AB Recent Developments Table 33. Cyclacel Pharmaceuticals, Inc. Company Information Table 34. Cyclacel Pharmaceuticals, Inc. Business Overview Table 35. Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 37. Cyclacel Pharmaceuticals, Inc. Recent Developments Table 38. ElexoPharm GmbH Company Information Table 39. ElexoPharm GmbH Business Overview Table 40. ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Product Portfolio Table 42. ElexoPharm GmbH Recent Developments Table 43. Ipsen S.A. Company Information Table 44. Ipsen S.A. Business Overview Table 45. Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Ipsen S.A. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 47. Ipsen S.A. Recent Developments Table 48. Isis Pharmaceuticals, Inc. Company Information Table 49. Isis Pharmaceuticals, Inc. Business Overview Table 50. Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 52. Isis Pharmaceuticals, Inc. Recent Developments Table 53. Orphagen Pharmaceuticals, Inc. Company Information Table 54. Orphagen Pharmaceuticals, Inc. Business Overview Table 55. Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 57. Orphagen Pharmaceuticals, Inc. Recent Developments Table 58. Pfizer Inc. Company Information Table 59. Pfizer Inc. Business Overview Table 60. Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Pfizer Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio Table 62. Pfizer Inc. Recent Developments Table 63. Novartis AG Company Information Table 64. Novartis AG Business Overview Table 65. Novartis AG Pituitary ACTH Hypersecretion Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Novartis AG Pituitary ACTH Hypersecretion Drug Product Portfolio Table 67. Novartis AG Recent Developments Table 68. Global Pituitary ACTH Hypersecretion Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Pituitary ACTH Hypersecretion Drug Sales by Region (2021-2026) & (K Units) Table 70. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Region (2021-2026) Table 71. Global Pituitary ACTH Hypersecretion Drug Sales by Region (2027-2032) & (K Units) Table 72. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Region (2027-2032) Table 73. Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region (2021-2026) Table 75. Global Pituitary ACTH Hypersecretion Drug Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Region (2027-2032) Table 77. North America Pituitary ACTH Hypersecretion Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 79. North America Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 80. North America Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Pituitary ACTH Hypersecretion Drug Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Pituitary ACTH Hypersecretion Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 84. Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 85. Europe Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Pituitary ACTH Hypersecretion Drug Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 89. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 90. Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Pituitary ACTH Hypersecretion Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 94. South America Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 95. South America Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Pituitary ACTH Hypersecretion Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2026) & (K Units) Table 99. Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2027-2032) & (K Units) Table 100. Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2026) & (K Units) Table 103. Global Pituitary ACTH Hypersecretion Drug Sales by Type (2027-2032) & (K Units) Table 104. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2026) Table 105. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2027-2032) Table 106. Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2026) Table 109. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2027-2032) Table 110. Global Pituitary ACTH Hypersecretion Drug Price by Type (2021-2026) & (US$/Unit) Table 111. Global Pituitary ACTH Hypersecretion Drug Price by Type (2027-2032) & (US$/Unit) Table 112. Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2026) & (K Units) Table 113. Global Pituitary ACTH Hypersecretion Drug Sales by Application (2027-2032) & (K Units) Table 114. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2026) Table 115. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2027-2032) Table 116. Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2026) Table 119. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2027-2032) Table 120. Global Pituitary ACTH Hypersecretion Drug Price by Application (2021-2026) & (US$/Unit) Table 121. Global Pituitary ACTH Hypersecretion Drug Price by Application (2027-2032) & (US$/Unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Pituitary ACTH Hypersecretion Drug Distributors List Table 125. Pituitary ACTH Hypersecretion Drug Customers List Table 126. Pituitary ACTH Hypersecretion Drug Industry Trends Table 127. Pituitary ACTH Hypersecretion Drug Industry Drivers Table 128. Pituitary ACTH Hypersecretion Drug Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pituitary ACTH Hypersecretion Drug Product Image Figure 5. Global Pituitary ACTH Hypersecretion Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Pituitary ACTH Hypersecretion Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Pituitary ACTH Hypersecretion Drug Sales (2021-2032) & (K Units) Figure 8. Global Pituitary ACTH Hypersecretion Drug Average Price (US$/Unit) & (2021-2032) Figure 9. ISIS-GCCRRx Product Image Figure 10. CORT-125134 Product Image Figure 11. COR-005 Product Image Figure 12. BIM-23A758 Product Image Figure 13. ATR-101 Product Image Figure 14. AT-814 Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. Others Product Image Figure 19. Global Pituitary ACTH Hypersecretion Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Pituitary ACTH Hypersecretion Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Pituitary ACTH Hypersecretion Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Pituitary ACTH Hypersecretion Drug Sales by Region in 2025 Figure 25. Global Pituitary ACTH Hypersecretion Drug Revenue by Region in 2025 Figure 26. North America Pituitary ACTH Hypersecretion Drug Market Size by Country in 2025 Figure 27. North America Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 28. North America Pituitary ACTH Hypersecretion Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Pituitary ACTH Hypersecretion Drug Market Size by Country in 2025 Figure 33. Europe Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Pituitary ACTH Hypersecretion Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Pituitary ACTH Hypersecretion Drug Market Size by Country in 2025 Figure 46. Asia Pacific Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue Market Share by Country (2021-2032) Figure 48. China Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Pituitary ACTH Hypersecretion Drug Market Size by Country in 2025 Figure 57. South America Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 58. South America Pituitary ACTH Hypersecretion Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Colombia Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Middle East and Africa Pituitary ACTH Hypersecretion Drug Market Size by Country in 2025 Figure 64. Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales Market Share by Country (2021-2032) Figure 65. Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue Market Share by Country (2021-2032) Figure 66. Egypt Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. South Africa Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Israel Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Türkiye Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. GCC Countries Pituitary ACTH Hypersecretion Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2032) Figure 72. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2032) Figure 73. Global Pituitary ACTH Hypersecretion Drug Price (US$/Unit) by Type (2021-2032) Figure 74. Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2032) Figure 75. Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2032) Figure 76. Global Pituitary ACTH Hypersecretion Drug Price (US$/Unit) by Application (2021-2032) Figure 77. Pituitary ACTH Hypersecretion Drug Value Chain Figure 78. Pituitary ACTH Hypersecretion Drug Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Pituitary ACTH Hypersecretion Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • ISIS-GCCRRx
  • CORT-125134
  • COR-005
  • BIM-23A758
  • ATR-101
  • AT-814
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Novartis AG

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Pituitary ACTH Hypersecretion Drug Market Size (2021-2032)
  4. 2.2.2 Global Pituitary ACTH Hypersecretion Drug Sales (2021-2032)
  5. 2.2.3 Global Pituitary ACTH Hypersecretion Drug Market Average Price (2021-2032)
  6. 2.3 Pituitary ACTH Hypersecretion Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 ISIS-GCCRRx
  9. 2.3.3 CORT-125134
  10. 2.3.4 COR-005
  11. 2.3.5 BIM-23A758
  12. 2.3.6 ATR-101
  13. 2.3.7 AT-814
  14. 2.3.8 Others
  15. 2.4 Pituitary ACTH Hypersecretion Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Pituitary ACTH Hypersecretion Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Pituitary ACTH Hypersecretion Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Pituitary ACTH Hypersecretion Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Pituitary ACTH Hypersecretion Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Pituitary ACTH Hypersecretion Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Pituitary ACTH Hypersecretion Drug, Established Date
  9. 3.9 Global Pituitary ACTH Hypersecretion Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Alder Biopharmaceuticals Inc.
  2. 4.1.1 Alder Biopharmaceuticals Inc. Company Information
  3. 4.1.2 Alder Biopharmaceuticals Inc. Business Overview
  4. 4.1.3 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Alder Biopharmaceuticals Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  6. 4.1.5 Alder Biopharmaceuticals Inc. Recent Developments
  7. 4.2 Corcept Therapeutics Incorporated
  8. 4.2.1 Corcept Therapeutics Incorporated Company Information
  9. 4.2.2 Corcept Therapeutics Incorporated Business Overview
  10. 4.2.3 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Corcept Therapeutics Incorporated Pituitary ACTH Hypersecretion Drug Product Portfolio
  12. 4.2.5 Corcept Therapeutics Incorporated Recent Developments
  13. 4.3 Cortendo AB
  14. 4.3.1 Cortendo AB Company Information
  15. 4.3.2 Cortendo AB Business Overview
  16. 4.3.3 Cortendo AB Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cortendo AB Pituitary ACTH Hypersecretion Drug Product Portfolio
  18. 4.3.5 Cortendo AB Recent Developments
  19. 4.4 Cyclacel Pharmaceuticals, Inc.
  20. 4.4.1 Cyclacel Pharmaceuticals, Inc. Company Information
  21. 4.4.2 Cyclacel Pharmaceuticals, Inc. Business Overview
  22. 4.4.3 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Cyclacel Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  24. 4.4.5 Cyclacel Pharmaceuticals, Inc. Recent Developments
  25. 4.5 ElexoPharm GmbH
  26. 4.5.1 ElexoPharm GmbH Company Information
  27. 4.5.2 ElexoPharm GmbH Business Overview
  28. 4.5.3 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 ElexoPharm GmbH Pituitary ACTH Hypersecretion Drug Product Portfolio
  30. 4.5.5 ElexoPharm GmbH Recent Developments
  31. 4.6 Ipsen S.A.
  32. 4.6.1 Ipsen S.A. Company Information
  33. 4.6.2 Ipsen S.A. Business Overview
  34. 4.6.3 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Ipsen S.A. Pituitary ACTH Hypersecretion Drug Product Portfolio
  36. 4.6.5 Ipsen S.A. Recent Developments
  37. 4.7 Isis Pharmaceuticals, Inc.
  38. 4.7.1 Isis Pharmaceuticals, Inc. Company Information
  39. 4.7.2 Isis Pharmaceuticals, Inc. Business Overview
  40. 4.7.3 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Isis Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  42. 4.7.5 Isis Pharmaceuticals, Inc. Recent Developments
  43. 4.8 Orphagen Pharmaceuticals, Inc.
  44. 4.8.1 Orphagen Pharmaceuticals, Inc. Company Information
  45. 4.8.2 Orphagen Pharmaceuticals, Inc. Business Overview
  46. 4.8.3 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Orphagen Pharmaceuticals, Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  48. 4.8.5 Orphagen Pharmaceuticals, Inc. Recent Developments
  49. 4.9 Pfizer Inc.
  50. 4.9.1 Pfizer Inc. Company Information
  51. 4.9.2 Pfizer Inc. Business Overview
  52. 4.9.3 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Inc. Pituitary ACTH Hypersecretion Drug Product Portfolio
  54. 4.9.5 Pfizer Inc. Recent Developments
  55. 4.10 Novartis AG
  56. 4.10.1 Novartis AG Company Information
  57. 4.10.2 Novartis AG Business Overview
  58. 4.10.3 Novartis AG Pituitary ACTH Hypersecretion Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Novartis AG Pituitary ACTH Hypersecretion Drug Product Portfolio
  60. 4.10.5 Novartis AG Recent Developments
5 Global Pituitary ACTH Hypersecretion Drug Market Scenario by Region
  1. 5.1 Global Pituitary ACTH Hypersecretion Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Pituitary ACTH Hypersecretion Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Pituitary ACTH Hypersecretion Drug Sales by Region: 2027-2032
  5. 5.3 Global Pituitary ACTH Hypersecretion Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Pituitary ACTH Hypersecretion Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Region: 2027-2032
  8. 5.4 North America Pituitary ACTH Hypersecretion Drug Market Facts & Figures by Country
  9. 5.4.1 North America Pituitary ACTH Hypersecretion Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Pituitary ACTH Hypersecretion Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Pituitary ACTH Hypersecretion Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Pituitary ACTH Hypersecretion Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Pituitary ACTH Hypersecretion Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Pituitary ACTH Hypersecretion Drug Market Facts & Figures by Country
  41. 5.7.1 South America Pituitary ACTH Hypersecretion Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Pituitary ACTH Hypersecretion Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Pituitary ACTH Hypersecretion Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Pituitary ACTH Hypersecretion Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Pituitary ACTH Hypersecretion Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Pituitary ACTH Hypersecretion Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Pituitary ACTH Hypersecretion Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Pituitary ACTH Hypersecretion Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Pituitary ACTH Hypersecretion Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Pituitary ACTH Hypersecretion Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Pituitary ACTH Hypersecretion Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Pituitary ACTH Hypersecretion Drug Value Chain Analysis
  2. 8.1.1 Pituitary ACTH Hypersecretion Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Pituitary ACTH Hypersecretion Drug Production Mode & Process
  5. 8.2 Pituitary ACTH Hypersecretion Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Pituitary ACTH Hypersecretion Drug Distributors
  8. 8.2.3 Pituitary ACTH Hypersecretion Drug Customers
9 Global Pituitary ACTH Hypersecretion Drug Analyzing Market Dynamics
  1. 9.1 Pituitary ACTH Hypersecretion Drug Industry Trends
  2. 9.2 Pituitary ACTH Hypersecretion Drug Industry Drivers
  3. 9.3 Pituitary ACTH Hypersecretion Drug Industry Opportunities and Challenges
  4. 9.4 Pituitary ACTH Hypersecretion Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst